Takeda Pharma files generic azilsartan NDA with MHLW
Takeda has submitted the NDA for the compound on the basis of the results from four Phase 3 clinical trials conducted in Japan. In those trials, Takeda has
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.